Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Current Taxes (2020 - 2023)

Historic Current Taxes for Cytek Biosciences (CTKB) over the last 4 years, with Q2 2023 value amounting to $1.9 million.

  • Cytek Biosciences' Current Taxes rose 4872.19% to $1.9 million in Q2 2023 from the same period last year, while for Jun 2023 it was $1.9 million, marking a year-over-year increase of 4872.19%. This contributed to the annual value of $1.4 million for FY2022, which is 4260.9% down from last year.
  • As of Q2 2023, Cytek Biosciences' Current Taxes stood at $1.9 million, which was up 4872.19% from $1.7 million recorded in Q1 2023.
  • In the past 5 years, Cytek Biosciences' Current Taxes registered a high of $2.7 million during Q1 2022, and its lowest value of $566000.0 during Q4 2020.
  • Over the past 4 years, Cytek Biosciences' median Current Taxes value was $1.4 million (recorded in 2022), while the average stood at $1.5 million.
  • Its Current Taxes has fluctuated over the past 5 years, first surged by 33745.58% in 2021, then plummeted by 4260.9% in 2022.
  • Cytek Biosciences' Current Taxes (Quarter) stood at $566000.0 in 2020, then surged by 337.46% to $2.5 million in 2021, then tumbled by 42.61% to $1.4 million in 2022, then surged by 35.12% to $1.9 million in 2023.
  • Its last three reported values are $1.9 million in Q2 2023, $1.7 million for Q1 2023, and $1.4 million during Q4 2022.